University of Iowa to use Bionano-based assay to replace most “gold standard” Southern blot tests for molecular diagnosis of FSHD SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc.

VANCOUVER, British Columbia, December 05, 2024--(BUSINESS WIRE)--SOLVE FSHD, a venture philanthropy organization dedicated to catalyzing innovation and overcoming barriers to accelerate new therapies ...

SOUTH SAN FRANCISCO, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- Epic Bio, a biotechnology company developing therapies to modulate gene expression using compact, non-cutting dCas proteins, today ...

An experimental RNA therapy from Avidity Biosciences has early clinical trial results showing it reduced by half the expression of a gene at the root of a rare, inherited form of muscular dystrophy ...

Avidity Biosciences said Wednesday morning that an experimental medicine successfully knocked down the gene behind a form of muscular dystrophy being pursued by a fleet of drug companies. The ...

The investigational drug losmapimod did not significantly change expression of the gene behind facioscapulohumeral muscular dystrophy (FSHD), but it was associated with potential improvements in ...

After years of advocating for a cure for the rare disease that has limited his mobility, Mark Christman has made his way to Capitol Hill. Christman, a retired attorney and board member of Trib Total ...

A 5K walk will be taking place this weekend in observance of a rare disease that many have never heard of. Joanne Dalessandro and her warriors will be in Barrington, Illinois, for the Chicagoland Walk ...

The third annual National FSHD Walk & Roll virtual event will take place on Sept. 12. With a goal of finding a cure to facioscapulohumeral muscular dystrophy (FSHD) by 2025, the FSHD Society’s third ...

SAN DIEGO, April 22, 2020 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that the University of Iowa Hospitals and Clinics (UIHC) will switch their method of clinical molecular ...